Pneumonia Vaccine Market : Global Market Estimation, Dynamics, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Pneumonia Vaccine Market: by Product Type (Prevnar 13, Synflorix, and Pneumovax 23), by Dosage (Single Dose Vial and Pre-filled Syringe), by End User (Child, Adult and Geriatric), by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Pneumonia Vaccine Market size is anticipated to grow at $4.5 billion till 2027, increasing at a CAGR of 4.76% during the forecast period 2020-2027. Pneumonia is an illness results into lung contamination in both the lungs due to the bacterial viruses and organisms. Pneumonia causes irritation around the sacs also referred as alveoli of the lungs results into causing breathing problems as alveoli fills with pus. Pneumococcal illnesses commonly found in young children but elder ones and adults are also more prone to this illness and even death. To get rid of the illness, pneumococcal vaccines are given to the children smaller than 2 years and to the adults. Such vaccines give relief from the bacteria, which make lungs infected by creating immunity in people. This vaccine has the potent to fight against 13 kinds of pneumococcal bacteria causing infection to the lungs. Pneumococcal polysaccharide vaccine is also referred as Pneumovax 23 (PPV-23). This vaccine is the first pneumococcal vaccine and crucial landmark in medical history derived from a capsular polysaccharide. This vaccine is hugely given to the adults who are at high risk. There are two vaccines types available. A conjugate vaccine contains polysaccharide antigen, which has the potent to improve the vaccine stability and efficacy. This vaccine segment greatly contributes towards the global pneumonia vaccine market growth. Infants and Children of 6 weeks to 5 years of age can take this vaccine for the prevention of pneumonia. However, the longer timetables necessary for the production of pneumococcal vaccines, as well as the greater costs associated with vaccine research, are impeding the market’s global expansion. Moreover, throughout the projected period, the development of protein-based vaccines for pneumonia is expected to generate chances for market advancement.

Pneumonia Vaccine Market

MARKET SUMMARY
-
4.76% CAGR
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 4.76%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Pneumonia Vaccine Market

  • The report on global Pneumonia Vaccine Market gives historical, current, and future market sizes (US$ Bn) on the basis of vaccine type, product type, sector, distribution channel and geography.
  • Pneumonia Vaccine Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • GlaxoSmithKline plc
  • Pfizer Inc
  • CSL Ltd
  • Merck & Co., Inc.,
  • Serum Institute of India Pvt. Ltd
Dynamics

Pneumonia Vaccine Market

The major factor that is driving the pneumococcal market growth is the prevalence of pneumococcal contagions. More than 250,000 people get admitted in the hospital because of pneumonia and almost 50000 people die in U.S according to National Center for Immunization and Respiratory illnesses. Moreover, the increasing awareness programs planned by the government are also impelling the growth of the market. Another prominent factor that contributes in the market growth is increasing vaccines production. The increasing government initiative on immunization programs to treat pneumonia, introduction of new pneumococcal vaccines and improving healthcare infrastructure are the two impelling factors greatly contribute in the pneumococcal polysaccharide vaccine market growth. Time consuming process of vaccine production and the high amount needed for the vaccine production are two major factors restrict the market growth.


North-America got significant share

North America accounted the huge market revenue size in the Pneumococcal Polysaccharide Vaccine Market in 2019 because of increasing investments in healthcare segment, growing cases of pneumococcal contagions and several key players operating in the market are developing novel treatment.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • This in-detail market report comprises of important insight focusing more on major market players around the globe
  • This research analysis provides a holistic assessment of the market for the forecasting period.
  • This market report depicts different segments, trend analysis and factors playing crucial role in the market
  • This research analysis also covers, factors, significant dynamics that involve opportunities, drivers, limits and challenges. Further, this market report also depicts the impact of the factors on the market growth.
  • This comprehensive market study focuses on the market development related to revenue gain during the forecast period.

Pneumonia Vaccine Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • GlaxoSmithKline plc
  • Pfizer Inc
  • CSL Ltd
  • Merck & Co., Inc.,
  • Serum Institute of India Pvt. Ltd
  • Sanofi Pasteur Inc.

Description

Pneumonia Vaccine Market size is anticipated to grow at $4.5 billion till 2027, increasing at a CAGR of 4.76% during the forecast period 2020-2027. Pneumonia is an illness results into lung contamination in both the lungs due to the bacterial viruses and organisms. Pneumonia causes irritation around the sacs also referred as alveoli of the lungs results into causing breathing problems as alveoli fills with pus. Pneumococcal illnesses commonly found in young children but elder ones and adults are also more prone to this illness and even death. To get rid of the illness, pneumococcal vaccines are given to the children smaller than 2 years and to the adults. Such vaccines give relief from the bacteria, which make lungs infected by creating immunity in people. This vaccine has the potent to fight against 13 kinds of pneumococcal bacteria causing infection to the lungs. Pneumococcal polysaccharide vaccine is also referred as Pneumovax 23 (PPV-23). This vaccine is the first pneumococcal vaccine and crucial landmark in medical history derived from a capsular polysaccharide. This vaccine is hugely given to the adults who are at high risk. There are two vaccines types available. A conjugate vaccine contains polysaccharide antigen, which has the potent to improve the vaccine stability and efficacy. This vaccine segment greatly contributes towards the global pneumonia vaccine market growth. Infants and Children of 6 weeks to 5 years of age can take this vaccine for the prevention of pneumonia. However, the longer timetables necessary for the production of pneumococcal vaccines, as well as the greater costs associated with vaccine research, are impeding the market’s global expansion. Moreover, throughout the projected period, the development of protein-based vaccines for pneumonia is expected to generate chances for market advancement.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX